News & Trends - Medical Technology

Legal supply of COVID-19 diagnostic tests

Health Industry Hub | March 25, 2020 |
[Total: 1    Average: 5/5]

MedTech News: To support efforts in managing the COVID-19 emergency, the Therapeutic Goods Administration (TGA) is working with suppliers to ensure that Australia has laboratory and point of care tests (POCT) available that are able to accurately detect COVID-19 infections.

There are two pathways to legally supply these types of tests.

  1. Undergoing an expedited TGA assessment of the COVID-19 test for inclusion on the Australian Register of Therapeutic Goods (ARTG). Once approved for inclusion on the ARTG, the COVID-19 test can be legally supplied in Australia.
  2. Supply of COVID-19 tests under the new Therapeutic Goods (Medical Devices Accredited Pathology Laboratories) (COVID-19 Emergency) Exemption 2020. This exemption permits importation, manufacture and supply of COVID-19 tests (that have not undergone TGA assessment) to accredited pathology laboratories.

Customer engagement during COVID-19. Health Industry Hub combines expertise in audience insights, delivering digital health content and measuring engagement with 20+ years industry experience. Created by industry for industry. Contact us.

The TGA has now approved the following tests for inclusion on the Australian Register of Therapeutic Goods (ARTG).

Expedited TGA assessment of COVID-19 diagnostic tests

COVID-19 is an emerging viral infectious disease. There is limited information available regarding the disease profile and the ability of available tests to accurately detect COVID-19 infections.

The TGA is currently undertaking an expedited assessment process based on the information and performance data currently available at the time of application for inclusion on the ARTG. All COVID-19 tests that are included on the ARTG based on this expedited assessment process are subject to additional non-standard conditions, which makes it easier for the TGA to perform additional post market assessments as experience and knowledge around COVID-19 diagnostic testing grows.

The conditions require that additional evidence to support the ongoing safety and performance of the devices be provided to the TGA within 12 months of approval.

Register FREE and join 20,000+ industry professionals who receive the latest industry news, innovations and insights from Health Industry Hub; the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.

Exemption for supply of COVID-19 tests to accredited pathology laboratories

A new emergency exemption, Therapeutic Goods (Medical Devices Accredited Pathology Laboratories) (COVID-19 Emergency) Exemption 2020, has been made to allow rapid supply of COVID-19 diagnostic tests to all Australian accredited pathology laboratories.

In practice this emergency exemption allows COVID-19 diagnostic tests to be immediately supplied to accredited pathology laboratories approved under the Health Insurance Act 1973, while the TGA continues to expedite the regulatory assessment process for these devices.

The exemption does not allow for general supply of rapid tests, including serological rapid tests intended for use at the point of care (POCT), other than to the accredited pathology laboratories specified in the exemption. Although, point of care tests (POCT) that have been included on the ARTG will be available for broader supply within Australia.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

News & Trends - Medical Technology

MedTech News - Siemens Healthineers to acquire Varian in $16.4bn deal

Siemens Healthineers to acquire Varian in $16.4bn deal

Health Industry Hub | August 5, 2020 |

MedTech News: Siemens Healthineers shall acquire Varian Medical Systems for approximately USD$16.4 billion. Since 2012, Siemens Healthineers and Varian have […]

More


News & Trends - Pharmaceuticals

Pharma News - New anti-cancer drug for prostate cancer

New anti-cancer drug for prostate cancer

Health Industry Hub | August 5, 2020 |

Pharma News: A new anti-cancer drug for prostate cancer overcomes the twin problems plaguing researchers for decades. It halts metastasis […]

More


News & Trends - Pharmaceuticals

Pharma News -

Popular high blood pressure drug linked to increased skin cancer risk

Health Industry Hub | August 5, 2020 |

Pharma News: Hydrochlorothiazide, a diuretic, is one of the most prescribed high blood pressure drugs and is used alone or […]

More


News & Trends - Pharmaceuticals

Pharma News - Australian triple therapy for COVID-19 cure and prevention

Australian triple therapy for COVID-19 cure and prevention

Health Industry Hub | August 5, 2020 |

Pharma News: The Centre for Digestive Disease (CDD) Medical Director Professor Thomas Borody says TGA and FDA approved Ivermectin, which […]

More